KPRX catalyst calendar

KIORA PHARMACEUTICALS INC

Upcoming catalysts
3
Cash runway
16 months
Cash & investments
$17M

KIORA PHARMACEUTICALS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 6, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 16 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 6, 2026 est. Next quarterly earnings (projected) Earnings —
November 15, 2026 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema Trial Milestone Phase 2
August 15, 2027 A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa Trial Milestone Phase 2

Track KPRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open KPRX in the tracker

Recent history

DateEventTypePhase
September 8, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
August 19, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 7, 2026 Quarterly results filed (8-K) Earnings —
June 18, 2026 8-K filed: Reg FD disclosure Filing —
June 11, 2026 8-K filed: Leadership change Corporate —
May 8, 2026 Quarterly results filed (8-K) Earnings —
April 7, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
April 2, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
March 25, 2026 Quarterly results filed (8-K) Earnings —
November 7, 2025 Quarterly results filed (8-K) Earnings —
August 13, 2025 8-K filed: Reg FD disclosure Filing —
August 8, 2025 Quarterly results filed (8-K) Earnings —
June 3, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
May 9, 2025 Quarterly results filed (8-K) Earnings —
January 9, 2024 A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease Trial Milestone Phase 2
August 10, 2023 A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) Trial Milestone Phase 1/Phase 2
December 22, 2022 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.